research Blocking Potassium Channels (Kv1.3): A New Treatment Option for Alopecia Areata?
Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.
Search
for
Sort by
Research
270-300 / 1000+ resultsresearch Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research INTERFERONS IN DERMATOLOGY
Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Synthesis and Pharmacological Evaluation of New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors
Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
research A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-α-Reductase in the Treatment of Androgenetic Alopecia
Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
research Advances in nucleoside monophosphate prodrugs as anti-HCV agents
New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.
research Remediation of prostrate-related disorders using polyphenols: kolaviron and quercetin in perspective
Kolaviron and quercetin may help treat prostate issues.
research Molecular Mechanism of Avicennia marina (Forssk.) Vierh. in Inhibiting Hepatitis C Virus Based on Network Pharmacology and Molecular Docking
Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
research Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
Vogt-Koyanagi-Harada disease can develop during interferon therapy for chronic hepatitis C.
research Development and evaluation of antisense shRNA-encoding plasmid loaded solid lipid nanoparticles against 5-α reductase activity
The new particle system could be a promising treatment for diseases related to the 5-α reductase enzyme.
research PD23-01 INHIBITOR OF 5A-REDUCTASE TYPES II PROMOTES THE INFILTRATION OF CD8+T CELLS IN BPH TISSUES.
Finasteride increases CD8+ T cells in BPH tissues.
research 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
research Enhanced skin permeation of 5α-reductase inhibitors entrapped into surface-modified liquid crystalline nanoparticles
Special nanoparticles increased skin absorption of hair loss treatments with fewer side effects.
research CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia
CDK4/6 inhibitors can protect hair cells from chemotherapy damage.
research Nano-spanlastics-loaded dissolving microneedle patches for ketotifen fumarate: advanced strategies for allergic conjunctivitis treatment and molecular insights
The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
research Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases
Ginsenoside compound K shows promise for treating metabolic diseases like obesity and diabetes, but more research is needed on its safety and effectiveness.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Kin‐cohort analysis of LRRK2‐G2019S penetrance in Parkinson's disease
The LRRK2-G2019S mutation in Parkinson's disease has a lifetime penetrance of 25-35%, and finasteride may help reduce symptoms in adult male Tourette syndrome patients.
research Experimental Evaluation of 3-meta-Pyridine-1,2,4-Oxadiazole Derivative of Deoxycholic Acid as a Prototype of 5-α-Reductase Inhibitors in In Silico and In Vivo Models
The new compound may be a safer alternative to finasteride for prostate protection.
research Therapeutic Updates on Lichen planopilaris and Frontal Fibrosing Alopecia: A Systematic Review
Antimalarial agents are effective for LPP, and intralesional steroids are effective for FFA.
research Charting the Bromodomain BRD4: Towards the Identification of Novel Inhibitors with Molecular Similarity and Receptor Mapping
Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
research Thrombocytopenia and Leukopenia Associated with Itraconazole
Itraconazole may cause low platelet and white blood cell counts.
research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial
research 026 Targeting pathogenic MICA-NKG2D interactions by statins: A novel adjunct treatment strategy for alopecia areata management?
Statins may help treat alopecia areata by reducing harmful immune interactions.
research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
research 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
Ritlecitinib may help treat alopecia areata by protecting hair follicles.